DOCSLIB.ORG

Principios Activos Fotosensibles

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Principios Activos Fotosensibles PRINCIPIOS ACTIVOS FOTOSENSIBLES PROTEGE A TUS PRODUCTOS DE LA FOTODEGRADACIÓN PRINCIPIOS ACTIVOS FOTOSENSIBLES Adenosine Carbamazepine Digitoxin Heptacaine Methaqualone-1-oxide Phenothiazines Sulfisomidine Tinidazole Vitamin D Adrenaline Carbisocaine Digoxin Hexachlorophane Methotrexate Phenylbutazone Sulpyrine Tolmetin Vitamin E Adriamycin Carboplatin Dihydroergotamin Hydralazine Metronidazole Phenylephrine Suprofen Tretinoin Vitamin K1 Amidopyrin Carmustine Dihydropyridines Mifepristone Phenytoin Triamcinolone Vitamin K2 Hydrochlorothiazide Suramin Amidinohydrazones Cefotaxime Diltiazem Hydrocortisone Minoxidil Physostigmine Triamterene Warfarin Amiloride Cefuroxime axetil Diosgenin Mitomycin C Piroxicam Tauromustine (TCNU) Trifluoperazine Hydroxychloroquine Terbutaline 4-Aminobenzoic acid Cephaeline Diphenhydramine Hypochloride Mitonafide Pralidoxime Trimethoprim Aminophenazone Cephalexine Dipyridamole Ibuprofen Mitoxantrone Prednisolone Tetracyclines Ubidecarenone Thiazide Aminophylline Cephradine Dithranol Imipramin Molsidomine Primaquine Vancomycin Thiocolchicoside Aminosalicylic acid Chalcone Dobutamin Indapamide Morphine Proguanil Vinblastine Thioridazine Amiodarone Chloramphenicol Dopamine Indomethacin Nalidixic acid Promazine Vitamin A Thiorphan Amodiaquine Chlordiazepoxide Dothiepin Indoprofen Naproxen Promethazine Vitamin B (see also Thiothixene Amonafide Chloroquine Doxorubicin Isoprenaline Neocarzinostatin Proxibarbital riboflavine) Tiaprofenic acid Amphotericin B Chlorpromazine DTIC Isopropylamino- Nimodipine Psoralen Vitamin C Amsacrine Chlortetracycline Epinephrine (see Adren- phenazone Nisoldipine Pyrazinamide Antimycotic agents Cianidanol aline) Isoproterenol Nitrazepam Quinidine L-Ascorbic acid (see Cinoxacin Epirubicin Ketoconazole Nitrendipine Quinine also vitamin C) Ciprofloxacin Ergotamine Ketoprofen Nitrobenzaldehydes Quinolones Azapropazon Cisplatin Etoposide Ketorolac tromethamine Nitrofurantoin Ranitidine Azathioprine Clofazimine Famotidine Levomepromazine Nitrofurazone Retinoic acid Aztreonam Clonazepam Fenofibrate Levonorgestrel Nitroglycerin Riboflavine Barbituric acid deriva- Colchicine Fentanyl Levothyroxine Nitroimidazole Rubidazone tives Contraceptives (see Flordipine Mebendazole Nitroprusside Salicylanilides Benorylate also steroids) Flucytosine Meclofenamic acid Noradrenaline (norepi- Salicylic acid Benoxaprofen Corticoids Flunitrazepam Medazepam nephrine) Sorivudine Benzamide Cytarabine 5-Fluorouracil Mefloquine Norfloxacin Spironolactone Benzocaine Dacarbazine Flurbiprofen Menadione Olaquindox Steroids Benzodiazepine Dapsone Flutamide Menatetrenone (see Oxolinic acid Succinylcholine Benzoquinones Daunorubicin Furnidipine Vitamin K2) Oxytocine Sulfacetamide Benzydamine Demeclocycline Furosemide 6-Mercaptopurine Pentacaine Sulfametoxazole Betamethasone Dichloracetamids Griseofulvin Methadone hydrochlo- Perazine Sulfanilamide Bleomycin Diclofenac Haloperidol ride Perphenazine Sulfathiazole Butibufen Diflunisal Phenazone PRINCIPIOS ACTIVOS FOTOSENSIBLES Adenosine Carbamazepine Digitoxin Heptacaine Methaqualone-1-oxide Phenothiazines Sulfisomidine Tinidazole Vitamin D Adrenaline Carbisocaine Digoxin Hexachlorophane Methotrexate Phenylbutazone Sulpyrine Tolmetin Vitamin E Adriamycin Carboplatin Dihydroergotamin Hydralazine Metronidazole Phenylephrine Suprofen Tretinoin Vitamin K1 Amidopyrin Carmustine Dihydropyridines Mifepristone Phenytoin Triamcinolone Vitamin K2 Hydrochlorothiazide Suramin Amidinohydrazones Cefotaxime Diltiazem Hydrocortisone Minoxidil Physostigmine Triamterene Warfarin Amiloride Cefuroxime axetil Diosgenin Mitomycin C Piroxicam Tauromustine (TCNU) Trifluoperazine Hydroxychloroquine Terbutaline 4-Aminobenzoic acid Cephaeline Diphenhydramine Hypochloride Mitonafide Pralidoxime Trimethoprim Aminophenazone Cephalexine Dipyridamole Ibuprofen Mitoxantrone Prednisolone Tetracyclines Ubidecarenone Thiazide Aminophylline Cephradine Dithranol Imipramin Molsidomine Primaquine Vancomycin Thiocolchicoside Aminosalicylic acid Chalcone Dobutamin Indapamide Morphine Proguanil Vinblastine Thioridazine Amiodarone Chloramphenicol Dopamine Indomethacin Nalidixic acid Promazine Vitamin A Thiorphan Amodiaquine Chlordiazepoxide Dothiepin Indoprofen Naproxen Promethazine Vitamin B (see also Thiothixene Amonafide Chloroquine Doxorubicin Isoprenaline Neocarzinostatin Proxibarbital riboflavine) Tiaprofenic acid Amphotericin B Chlorpromazine DTIC Isopropylamino- Nimodipine Psoralen Vitamin C Amsacrine Chlortetracycline Epinephrine (see Adren- phenazone Nisoldipine Pyrazinamide Antimycotic agents Cianidanol aline) Isoproterenol Nitrazepam Quinidine L-Ascorbic acid (see Cinoxacin Epirubicin Ketoconazole Nitrendipine Quinine also vitamin C) Ciprofloxacin Ergotamine Ketoprofen Nitrobenzaldehydes Quinolones Azapropazon Cisplatin Etoposide Ketorolac tromethamine Nitrofurantoin Ranitidine Azathioprine Clofazimine Famotidine Levomepromazine Nitrofurazone Retinoic acid Aztreonam Clonazepam Fenofibrate Levonorgestrel Nitroglycerin Riboflavine Barbituric acid deriva- Colchicine Fentanyl Levothyroxine Nitroimidazole Rubidazone tives Contraceptives (see Flordipine Mebendazole Nitroprusside Salicylanilides Benorylate also steroids) Flucytosine Meclofenamic acid Noradrenaline (norepi- Salicylic acid Benoxaprofen Corticoids Flunitrazepam Medazepam nephrine) Sorivudine Benzamide Cytarabine 5-Fluorouracil Mefloquine Norfloxacin Spironolactone Benzocaine Dacarbazine Flurbiprofen Menadione Olaquindox Steroids Benzodiazepine Dapsone Flutamide Menatetrenone (see Oxolinic acid Succinylcholine Benzoquinones Daunorubicin Furnidipine Vitamin K2) Oxytocine Sulfacetamide Benzydamine Demeclocycline Furosemide 6-Mercaptopurine Pentacaine Sulfametoxazole Betamethasone Dichloracetamids Griseofulvin Methadone hydrochlo- Perazine Sulfanilamide Bleomycin Diclofenac Haloperidol ride Perphenazine Sulfathiazole Butibufen Diflunisal Phenazone PRINCIPIOS ACTIVOS FOTOSENSIBLES Adenosine Carbamazepine Digitoxin Heptacaine Methaqualone-1-oxide Phenothiazines Sulfisomidine Tinidazole Vitamin D Adrenaline Carbisocaine Digoxin Hexachlorophane Methotrexate Phenylbutazone Sulpyrine Tolmetin Vitamin E Adriamycin Carboplatin Dihydroergotamin Hydralazine Metronidazole Phenylephrine Suprofen Tretinoin Vitamin K1 Amidopyrin Carmustine Dihydropyridines Mifepristone Phenytoin Triamcinolone Vitamin K2 Hydrochlorothiazide Suramin Amidinohydrazones Cefotaxime Diltiazem Hydrocortisone Minoxidil Physostigmine Triamterene Warfarin Amiloride Cefuroxime axetil Diosgenin Mitomycin C Piroxicam Tauromustine (TCNU) Trifluoperazine Hydroxychloroquine Terbutaline 4-Aminobenzoic acid Cephaeline Diphenhydramine Hypochloride Mitonafide Pralidoxime Trimethoprim Aminophenazone Cephalexine Dipyridamole Ibuprofen Mitoxantrone Prednisolone Tetracyclines Ubidecarenone Thiazide Aminophylline Cephradine Dithranol Imipramin Molsidomine Primaquine Vancomycin Thiocolchicoside Aminosalicylic acid Chalcone Dobutamin Indapamide Morphine Proguanil Vinblastine Thioridazine Amiodarone Chloramphenicol Dopamine Indomethacin Nalidixic acid Promazine Vitamin A Thiorphan Amodiaquine Chlordiazepoxide Dothiepin Indoprofen Naproxen Promethazine Vitamin B (see also Thiothixene Amonafide Chloroquine Doxorubicin Isoprenaline Neocarzinostatin Proxibarbital riboflavine) Tiaprofenic acid Amphotericin B Chlorpromazine DTIC Isopropylamino- Nimodipine Psoralen Vitamin C Amsacrine Chlortetracycline Epinephrine (see Adren- phenazone Nisoldipine Pyrazinamide Antimycotic agents Cianidanol aline) Nitrazepam Quinidine Referencia: PHOTOSTABILITY OF DRUGS AND DRUG, FORMULATIONS, Second Edition, Edited by: Isoproterenol Hanne Hjorth Tønnesen, 2004 by CRC Press LLC L-Ascorbic acid (see Cinoxacin Epirubicin Ketoconazole Nitrendipine Quinine also vitamin C) Ciprofloxacin Ergotamine Ketoprofen Nitrobenzaldehydes Quinolones Azapropazon Cisplatin Etoposide Ketorolac tromethamine Nitrofurantoin Ranitidine Azathioprine Clofazimine Famotidine Levomepromazine Nitrofurazone Retinoic acid Aztreonam Clonazepam Fenofibrate Levonorgestrel Nitroglycerin Riboflavine CDMX Barbituric acid deriva- Colchicine Fentanyl Levothyroxine Nitroimidazole Rubidazone tives Contraceptives (see Flordipine Mebendazole Nitroprusside Salicylanilides CURSO Benorylate also steroids) Flucytosine Meclofenamic acid Noradrenaline (norepi- Salicylic acid Benoxaprofen Corticoids Flunitrazepam Medazepam nephrine) Sorivudine Lore Benzamide Cytarabine 5-Fluorouracil Mefloquine Norfloxacin Spironolactone m Estudios de fotoestabilidad de Benzocaine Dacarbazine Flurbiprofen Menadione Olaquindox Steroids Benzodiazepine Dapsone Flutamide Menatetrenone (see Oxolinic acid Succinylcholine medicamentos Benzoquinones Daunorubicin Furnidipine Vitamin K2) Oxytocine Sulfacetamide Benzydamine Demeclocycline Furosemide 6-Mercaptopurine Pentacaine Sulfametoxazole Betamethasone Dichloracetamids Griseofulvin Methadone hydrochlo- Perazine Sulfanilamide 30 de Abril de 2019 Bleomycin Diclofenac Haloperidol ride Perphenazine Sulfathiazole Butibufen Diflunisal Phenazone (55) 4781 - 0505 [email protected] Rómulo Valdez # 86, Colonia Presidentes Ejidales, Coyoacán Consulta el temario en: www.consufarma.com.
Load more

Recommended publications
  • WHO Pharmaceuticals Newsletters
    2021 WHO Pharmaceuticals No.1 NEWSLETTER The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicines WHO Vision for Medicines Safety and legal actions taken by regulatory authorities around No country left behind: the world. It also provides signals based on information worldwide pharmacovigilance for safer medicines, safer patients derived from the WHO global database of individual case safety reports, VigiBase. In addition, this edition of the Newsletter includes a The aim of the Newsletter is to disseminate regulatory summary of discussions and key recommendations of information on the safety of Advisory Committee on Safety of Medicinal Products pharmaceutical products, (ACSoMP) Seventeenth meeting. based on communications received from our network of national pharmacovigilance centres and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from: Safety and Vigilance: Medicines, EMP-HIS, World Health Organization, 1211 Geneva 27, Switzerland, Contents E -mail address: [email protected] This Newsletter is also available at: Regulatory matters http://www.who.int/medicines Safety of medicines Signal Feature WHO Pharmaceuticals Newsletter No. 1, 2021 ISBN 978-92-4-002136-5 (electronic version) ISBN 978-92-4-002137-2 (print version) © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • The Nitroimidazole Family of Drugs
    Br J Vener Dis: first published as 10.1136/sti.54.2.69 on 1 April 1978. Downloaded from British Journal of Venereal Diseases, 1978, 54, 69-71 Editorial The nitroimidazole family of drugs In 1955 an antibiotic complex isolated from a operative infection caused by susceptible anaerobes, strain of Streptomyces on the island of Reunion particularly in gynaecological surgery, appendi- was found by research workers of Rhone-Poulenc in cectomy, and colonic surgery. Paris to contain a trichomonacidal antibiotic- Real innovations in chemotherapy, such as azomycin. It had previously been isolated in Japan metronidazole, always attract attention from other (Maeda et al., 1953) and identified as 2-nitroimi- research groups. Although interest was slow to dazole (Ia see Table) (Nakamura, 1955). At the develop, research workers have sought analogous, time, and for some years after, this remarkably structurally-modified compounds which might afford simple compound defied synthesis, but it stimulated some advantage in clinical use-for example, the workers at Rhone-Poulenc to prepare and test greater potency, better tolerance and freedom from the activity of the more readily accessible isomeric side effects, a broader spectrum of action, a longer 5-nitroimidazoles (II). It was their good fortune in duration of action, or in some other characteristic. 1957 to find that these isomers were more active This effort has been concerned with important antiprotozoal agents than the natural product veterinary uses of 5-nitroimidazoles as well as the (Cosar and Julou, 1959). In a series of 150 related applications in human medicine. compounds, the one with a P-hydroxyethyl group Metronidazole has been a difficult target to in the 1-position gave the best compromise between improve upon, but several other drugs of this activity and toxicity and this brand of metroni- chemical family have been introduced to clinical dazole was introduced as Flagyl.
    [Show full text]
  • STOP TEST for PHARMACEUTICAL ANALYSIS 1 Point
    Generated by Foxit PDF Creator © Foxit Software http://www.foxitsoftware.com For evaluation only. STOP TEST FOR PHARMACEUTICAL ANALYSIS 1 point 1. Indicator for direct aqueous titration is: a) potassium permanganate b) bromcresol green c) tropeolin OO d) phenophythaleine e) all answers are not correct 2. Indicator for direct non – aqueous titration of bases is: a) crystalviolet b) potassiun chromate c) methylorange d) methylene blue e) all answers are not correct 3. Titrant for direct non – aqueous titration of bases is: a) HCl b) AgNO3 c) H2SO4 d) HClO4 in CH3COOH e) all answers are not correct 4. Titrant for direct complexometric method is: a) NaNO2 b) KBrO 3 c) I2 d) KIO3 e) all answers are not correct 5. The name of direct argentometric titration is method of: a) Bouge – Lambert b) Schmidt – Kolbe c) Mor d) Traube e) all answers are not correct Generated by Foxit PDF Creator © Foxit Software http://www.foxitsoftware.com For evaluation only. 6. The name of indirect argentometric titration is method of: a) Folchard b) Hanch c) Kolbe – Schmidt d) Beer e) all answers are not correct 7. In titration with perchloric acid in glacials acetic acid to the determined hydrochoride of base is added: а) mercury acetate b) mercury chloride c) potassium bromide d) imidazole – mercury reactive e) all answers are not correct 8. In accordance to European Pharmacopoeia by direct cerimetry are determined the following substances: a) Paracetamol b) Ascorbic acid c) Nifedipine d) answers a), b), c) are correct e) answers a), b), c) are not correct 9. According to European Pharmacopoeia substances Menadione and Рaracеtamol are determined by: а) HPLC b) TLC c) spectrophotometry d) indirect cerimetry e) all answers are not correct 10.
    [Show full text]
  • WO 2U11/154U12 a L
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 15 December 2011 (15.12.2011) WO 2U11/154U12 A l (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/415 (2006.01) A61K 9/20 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/DK201 1/050207 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 10 June 201 1 (10.06.201 1) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2010 00506 10 June 2010 (10.06.2010) DK Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): LIFE- GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, CYCLE PHARMA A S [DK/DK]; Kogle Alle 4, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, DK-2970 H0rsholm (DK).
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Myofascial Pain Syndrome: a Treatment Review Mehul J
    Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Anesthesiology and Critical Care Medicine Faculty Anesthesiology and Critical Care Medicine Publications 6-2013 Myofascial pain syndrome: A treatment review Mehul J. Desai George Washington University Vikramjeet Saini Shawnjeet Saini Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_anesth_facpubs Part of the Anesthesia and Analgesia Commons Recommended Citation Desai, M. J., Saini, V., & Saini, S. (2013). Myofascial Pain Syndrome: A Treatment Review. Pain and Therapy, 2(1), 21–36. This Journal Article is brought to you for free and open access by the Anesthesiology and Critical Care Medicine at Health Sciences Research Commons. It has been accepted for inclusion in Anesthesiology and Critical Care Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact [email protected]. Pain Ther (2013) 2:21–36 DOI 10.1007/s40122-013-0006-y REVIEW Myofascial Pain Syndrome: A Treatment Review Mehul J. Desai • Vikramjeet Saini • Shawnjeet Saini To view enhanced content go to www.paintherapy-open.com Received: September 27, 2012 / Published online: February 12, 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com ABSTRACT and nonpharmacologic treatments, the authors aim to provide clinicians with a more Myofascial pain syndrome (MPS) is defined as comprehensive knowledge of the interventions pain that originates from myofascial trigger for myofascial pain. points in skeletal muscle. It is prevalent in regional musculoskeletal pain syndromes, either alone or in combination with other pain Keywords: Analgesics; Anticonvulsants; generators. The appropriate evaluation and Muscle relaxants; Myofascial pain; management of myofascial pain is an important Nonpharmacological treatment; Pain; part of musculoskeletal rehabilitation, and Treatment regional axial and limb pain syndromes.
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • Promotion of Bone Formation by Fermented Soybean (Natto) Intake in Premenopausal Women
    J Nutr Sci Vitaminol, 50,114-120, 2004 Promotion of Bone Formation by Fermented Soybean (Natto) Intake in Premenopausal Women Hironobu KATSUYAMA1,Seiji IDEGUCHI2,Masao FUKUNAGA3, Tatsushige FUKUNAGA4, Kiyofumi SAIJOHSand Shigeo SUNAMII Departments of 1Public Health, 2Health Care Medicine arid 3NuclearMedicine , Kawasaki Medical School,Kurashiki 701-0192, Japan 4Departrnent of Forensic Medicine and Sciences , Mie University School of Medicine, Tsu 514-8507, Japan 5Department of Hygiene , Kanazawa University School of Medicine and Graduate School of Medical Sciences, Kanazawa 920-8640, Japan (Received July 24, 2003) Summary A therapeutic agent of vitamin K2 is approved for the treatment of osteoporosis in Japan. However, little is known about the efficacy of dietary intake of vitamin K2for bone health. We compared the effects of various levels of fermented soybeans (Natto) intake , which contains plenty of vitamin K2, on bone stiffness and bone turnover markers in healthy premenopausal women, Seventy-three healthy premenopausal women were ran domly divided into four groups matched for age and parity categories . Natto was supplied as follows: Group 1(no intake), Group 2 (once per month), Group 3 (once per week) and Group 4 (three times per week). Subjects took Natto at a lunch for 1 y, and the stiffness index by quantitative ultrasound and bone turnover markers were assessed at baseline, 6 mo and 1 y There was no statistical difference in the stiffness index during the 1 y observation . How ever, bone specific alkaline phosphatase (BAP) in Group 4 was higher than that in Group 3 at 1 y and undercarboxylated osteocalcin (Glu) in Group 4 was significantly lower than those in Groups 1, 2 and 3 at 6 mo.
    [Show full text]
  • Pharmaceuticals and Medical Devices Safety Information No
    Pharmaceuticals and Medical Devices Safety Information No. 215 July 2005 Table of Contents 1. Important Safety Information ································································ 2 .1. Ethionamide ······················································································ 2 .2. Etodolac ···························································································· 5 .3. Gemcitabine Hydrochloride ····························································· 10 .4. Omeprazole, Omeprazole Sodium ·················································· 12 2. Revision of PRECAUTIONS (No.167) Tiaprofenic Acid (and 17 others) ·································································· 16 3. List of products subject to Early Post-marketing Phase Vigilance ·············································· 23 This Pharmaceuticals and Medical Devices Safety Information (PMDSI) is issued based on safety information collected by the Ministry of Health, Labour and Welfare. It is intended to facilitate safer use of pharmaceuticals and medical devices by healthcare providers. PMDSI is available on the Pharmaceuticals and Medical Devices Agency website (http://www.pmda.go.jp/english/index.html) and on the MHLW website (http://www.mhlw.go.jp/, Japanese only). Published by Translated by Pharmaceutical and Food Safety Bureau, Pharmaceuticals and Medical Devices Agency Ministry of Health, Labour and Welfare Pharmaceutical and Food Safety Bureau, Office of Safety, Ministry of Health, Labour and Welfare Pharmaceuticals and Medical
    [Show full text]